Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Aschaffenburg – page 63

1 096 clinical trials in Aschaffenburg, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Aschaffenburg at a glance
1 096
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 096 trials in Aschaffenburg

Open in trial search

Study Comparing Datopotamab Deruxtecan and Docetaxel for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Daiichi Sankyo Inc.

Aortic stenosis

Not recruiting

Study of spironolactone and Dihydralazine for reducing heart muscle scarring in patients with severe aortic valve narrowing after valve replacement procedure

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Spironolactone
  • Sponsor:Universitaetsmedizin Goettingen

Study of Rapcabtagene Autoleucel and Ibrutinib for Adults with Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Other Blood Cancers

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Novartis Pharma AG

Plasma cell myeloma

Not recruiting

Study comparing iberdomide, daratumumab and dexamethasone versus daratumumab, bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Celgene Corp.

Study Comparing XL092 and Atezolizumab with Regorafenib for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Exelixis Inc.

Plasma cell myeloma

Not recruiting

Study on Adding Isatuximab to Lenalidomide, Bortezomib, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Acute myeloid leukaemia+1

Not recruiting

Study Comparing Gilteritinib and Midostaurin with Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with FLT3 Mutation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Gilteritinib
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Anal cancer stage II+1

Not recruiting

Study on Durvalumab with Radiochemotherapy for Patients with Locally-Advanced Anal Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Goethe University Frankfurt

Gastrooesophageal cancer+1

Not recruiting

Study on Organ Preservation for Early Stage Esophageal Cancer Using Durvalumab and Chemoradiation for Patients Eligible for Surgery

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Migraine

Not recruiting

Study on Rimegepant for Treating Migraine in Adults Who Cannot Use Triptans

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Rimegepant
  • Sponsor:Pfizer Inc.

Migraine

Not recruiting

Study on Rimegepant for Preventing Migraines in Adults with Poor Response to Oral Preventive Medications

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Rimegepant
  • Sponsor:Pfizer Inc.

Acute kidney injury

Not recruiting

Study on TIN816 for Preventing Acute Kidney Injury in Adults Undergoing Cardiac Surgery

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:TIN816
  • Sponsor:Novartis Pharma AG

Other cities in Germany

The busiest research cities in the country

All 503 cities in Germany

Clinical research in Aschaffenburg

What the registry says about research in the country

01 Hematologic Oncology

Groundbreaking research focusing on acute myeloid leukemia and chronic lymphocytic leukemia, evaluating novel therapeutic approaches including targeted therapies and combination treatments. Studies examine innovative drug combinations to improve patient outcomes in various blood cancers.

  • FLT3-mutation targeted therapies
  • Chemotherapy optimization
  • Novel drug combinations

Multiple trials investigating treatments for both newly diagnosed and relapsed/refractory patients.

02 Breast Cancer Research

Advanced studies in hormone receptor-positive breast cancer, particularly focusing on metastatic disease. Investigations include new combination therapies and targeted treatments for patients with specific genetic mutations.

  • ESR1-mutation treatments
  • CDK4/6 inhibitor combinations
  • Endocrine therapy resistance

Research emphasizes personalized treatment approaches based on molecular profiles.

03 Respiratory Medicine

Innovative research in severe asthma treatment, particularly focusing on patients with eosinophilic phenotype. Studies evaluate new biological therapies and compare their efficacy with existing treatments.

  • Anti-IL-5/5R therapy
  • Long-term efficacy studies
  • Phenotype-specific treatments

Trials aim to improve long-term management of severe respiratory conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.